Corcept Therapeutics Inc. (CORT) has received FDA approval for Lifyorli (relacorilant) in combination with nab-paclitaxel, targeting adults with platinum-resistant ovarian cancer. This marks a significant milestone as Lifyorli becomes the first FDA-approved selective glucocorticoid receptor antagonist (SGRA), following positive results from the pivotal ROSELLA trial involving 381 patients. The approval is pivotal for Corcept, which is also pursuing relacorilant’s applications in other cancer types, including endometrial and pancreatic cancers.
The approval has had an immediate impact on Corcept’s stock performance, with shares surging 19.66% to close at $40.47, and continuing to rise in after-hours trading to $42.57. This momentum reflects investor optimism about the drug’s potential in a market with limited treatment options for platinum-resistant ovarian cancer, which could translate into significant revenue streams for the company.
For market professionals, Corcept’s advancements and the FDA approval represent a potential growth opportunity within the oncology sector, particularly as the company seeks further regulatory approvals in Europe and expands its drug portfolio.
Source: nasdaq.com